Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, all. Damian here with a look at the future of treating Duchenne muscular dystrophy, the departure of an influential biotech CEO, and the next phase of the GLP-1 panic.
The need-to-know this morning
• Novo Nordisk reported third-quarter earnings of 5 Danish krone per share on total revenue of 58.73 billion krone — 29% higher year over year and topping consensus estimates. Sales of GLP-1 obesity drug Wegovy rose 28% to 9.65 billion krone, or $1.4 billion — beating consensus. Sales of the diabetes drug Ozempic were 23.9 billion krone, or $4.2 billion.
• Eli Lilly reported third-quarter adjusted earnings of 10 cents per share on total revenue of $9.5 billion — ahead of consensus. Sales of the diabetes drug Mounjaro were $1.4 billion, better than expected.
• Regeneron Pharmaceuticals reported third-quarter adjusted earnings of $11.59 per share on total revenue of $3.36 billion — ahead of consensus. Sales of Eylea were $1.49 billion.
• Moderna reported an adjusted third-quarter loss of $9.53 per share, driven by mostly non-cash charges related to resizing its manufacturing capacity and tax allowances. Revenue was $1.83 billion, a decrease of 47% related to lower sales of its Spikevax Covid vaccine, but still topping Wall Street’s consensus.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect